stockrowInsulet Corporation
PODD Healthcare Medical Devices
Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024.
- Revenue
- +19.2%
- EPS
- +64.1%
- Free cash flow
- −29.8%
- Total debt
- −5.19%
Quarter to September 2026, against a year earlier
Follow PODD
Alert me
Insulet Corporation (PODD) Shares outstanding
Insulet Corporation's shares outstanding at the end of fiscal 2025 was $71.9M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $69.5M. Over the past ten years it has ranged from $56.8M (fiscal 2015) to $73.9M (fiscal 2024); the current reading is higher than 82% of that period. Insulet Corporation ranks 41st of 147 Medical Devices companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $71.9M | (2.71%) |
| FY2024 | $73.9M | 0.35% |
| FY2023 | $73.6M | 5.33% |
| FY2022 | $69.9M | 1.94% |
| FY2021 | $68.6M | 3.99% |
| FY2020 | $65.9M | 5.85% |
| FY2019 | $62.3M | 2.12% |
| FY2018 | $61.0M | 5.18% |
| FY2017 | $58.0M | 1.31% |
| FY2016 | $57.3M | 0.82% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $69.5M | 0.13% |
| Jun 2026 | $69.4M | (1.14%) |
| Mar 2026 | $70.2M | (2.34%) |
| Dec 2025 | $71.9M | 1.73% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | $449.4M |
| BRKR Bruker Corporation compare | $152.5M |
| GMED Globus Medical, Inc. compare | $136.0M |
| TXG 10x Genomics compare | $130.0M |
| PODD Insulet Corporation | $69.5M |
| GKOS Glaukos Corporation compare | $61.2M |
| PEN Penumbra, Inc. compare | $39.6M |
| BIO.B Bio-Rad Laboratories, Inc. compare | $26.9M |
| BIO Bio-Rad Laboratories, Inc. compare | $26.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on PODD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement